Business
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
COPENHAGEN, Denmark, December 12, 2025--Genmab A/S (Nasdaq: GMAB) ("Genmab") announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the "Offer") by Genmab Holding II B.V., a wholly owned subsidiary of Genmab ("Purchaser"), to acquire all the issued and outstanding common shares of Merus N.V. (Nasdaq: MRUS) ("Merus") for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab’s shift to a who
About this update from Genmab A/s
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1301,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/8e3a2bd44bd337e4906f36836a813c48"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gKeTMRpTdVXmmLwxB_KlYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8e3a2bd44bd337e4906f36836a813c48","width":960,"height":280},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/sbVX8gXqNgccRdCsJw5Z.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/8e3a2bd44bd337e4906f36836a813c48","width":1200,"height":350}},"lazy":false},{"type":"text","content":"Company Announcement","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio","length":115,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Transaction anticipated to be accretive to Genmab’s EBITDA by end of 2029","length":73,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":188,"olType":false},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"COPENHAGEN, Denmark, December 12, 2025--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) ("Genmab") announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the "Offer") by Genmab Holding II B.V., a wholly owned subsidiary of Genmab ("Purchaser"), to acquire all the issued and outstanding common shares of Merus N.V. (Nasdaq: MRUS) ("Merus") for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates Genmab’s shift to a wholly owned model, expanding and diversifying the company’s revenue, driving sustained growth into the next decade and contributing to Genmab’s evolution into a biotechnology leader.","length":737,"tagName":"p"},{"type":"text","content":""The Merus acquisition marks a pivotal step in the delivery of Genmab’s long-term strategy and strengthens our path to becoming a global biotechnology leader with sustained growth and profitability. We are energized by the potential of petosemtamab to meaning...